Pain--mechanics and management.
In the past two decades there has been remarkable progress in understanding the neural mechanisms of pain. However, chronic pain is poorly understood and, by definition, poorly managed. In addition to hyperactivity of the sympathetic nervous system and damage to normal inhibitory mechanisms, social and psychological factors play a major role in producing the disability of chronic pain. New approaches to manage chronic pain include nonopiate drugs, transcutaneous electral nerve stimulation and psychological and behavioral methods. A nervous system network has recently been described that suppresses pain. This analgesic action is mediated by endogenous opioid peptides (endorphins) and by biogenic amines. The analgesia network can be activated either by electral stimulation or by opiates such as morphine or methadone.
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001095:Arachidonic Acids / Q000378:metabolism; D001341:Autonomic Nervous System / Q000503:physiopathology; D002908:Chronic Disease; D006801:Humans; D009475:Neurons, Afferent / Q000502:physiology; D009619:Nociceptors / Q000503:physiopathology; D010146:Pain / Q000503:physiopathology*; D059408:Pain Management; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012684:Sensory Thresholds; D013373:Substance P / Q000502:physiology; D013565:Sympatholytics / Q000627:therapeutic use; D004561:Transcutaneous Electric Nerve Stimulation
D000701:Analgesics, Opioid; D000893:Anti-Inflammatory Agents; D000929:Antidepressive Agents, Tricyclic; D001095:Arachidonic Acids; D011619:Psychotropic Drugs; D013565:Sympatholytics; D013373:Substance P